Lyra Therapeutics (LYRA) Revenue & Revenue Breakdown
Lyra Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.53M
Latest Revenue (Q)
$183.00K
Lyra Therapeutics Revenue by Period
Lyra Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $1.53M | -1.54% |
| 2023-12-31 | $1.56M | 14.31% |
| 2022-12-31 | $1.36M | 378.25% |
| 2021-12-31 | $285.00K | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2018-12-31 | $1.24M | - |
Lyra Therapeutics generated $1.53M in revenue during NA 2024, up -1.54% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Lyra Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $183.00K | - |
| 2025-03-31 | $183.00K | -12.44% |
| 2024-12-31 | $209.00K | 7.18% |
| 2024-09-30 | $195.00K | -67.39% |
| 2024-06-30 | $598.00K | 12.41% |
| 2024-03-31 | $532.00K | 264.38% |
| 2023-12-31 | $146.00K | -73.16% |
| 2023-09-30 | $544.00K | 18.78% |
| 2023-06-30 | $458.00K | 11.71% |
| 2023-03-31 | $410.00K | 3627.27% |
| 2022-12-31 | $11.00K | -96.94% |
| 2022-09-30 | $359.00K | -11.79% |
| 2022-06-30 | $407.00K | -92.42% |
| 2022-03-31 | $5.37M | 1880.44% |
| 2021-12-31 | $271.00K | 1835.71% |
| 2021-09-30 | $14.00K | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Lyra Therapeutics generated $183.00K in revenue during Q2 2025, up 0.00% compared to the previous quarter, and up 34.40% compared to the same period a year ago.
Lyra Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MRKR | Marker Therapeutics | $6.59T | $349.10K |
| BOLT | Bolt Biotherapeutics | $7.69M | $1.22M |
| EVGN | Evogene | $5.64M | $4.19M |
| IMRN | Immuron | $1.80M | $2.36M |
| LYRA | Lyra Therapeutics | $1.53M | $183.00K |
| ABP | Abpro | $122.00K | - |
| DWTX | Dogwood Therapeutics | - | - |
| ACXP | Acurx Pharmaceuticals | - | - |
| KALA | KALA BIO | - | - |
| RNAZ | TransCode Therapeutics | - | - |
| INTS | Intensity Therapeutics | - | - |